|
|
Article: CombinatoRx Raises $40M In Series C To Fund Clinical Trials.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Moving at the pace of a busy bartender, CombinatoRx Inc. raised $40.3 million in its Series C round of financing and is poised to enter the clinic less than three years after officially opening its doors in March 2000.
Joanna Horobin, executive vice president and chief operating officer at CombinatoRx, said there were certain elements of the company that allowed for the round of notable size.
"One of the first keys is that we are doing something that is really novel and different," she told BioWorld Today. "The second thing is the speed with which the company has done what it set out to do two years ago."
Two years ...
Related newspaper, magazine, and journal articles:
|
|
Article: CombinatoRx, Covidien Shares Fall on Exalgo FDA Review.
BIOWORLD Today;
September 23, 2009 ;
700+ words
... ... WASHINGTON -- Shares of CombinatoRx Inc. plunged 17 percent ... stock merger deal with CombinatoRx, expected to close in ... the drug in June. (See BioWorld Today, July 2, 2009.) Shares of CombinatoRx (NASDAQ:CRXX) closed ...
|
|